Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
December 13, 2023 18:05 ET
|
Rain Oncology Inc.
NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”)...
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023 16:01 ET
|
Rain Oncology Inc.
NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended September 30, 2023, along with an update on...
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
October 16, 2023 08:00 ET
|
Rain Oncology Inc.
NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra...
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023 16:05 ET
|
Rain Oncology Inc.
– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations...
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023
July 26, 2023 08:00 ET
|
Rain Oncology Inc.
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and...
Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs
May 30, 2023 08:30 ET
|
Rain Oncology Inc.
– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial – – Evaluation of outcomes from the...
Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium
November 23, 2022 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
Rain Therapeutics to Participate in Piper Sandler’s 34th Annual Healthcare Conference
November 18, 2022 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting
November 17, 2022 13:05 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference
November 14, 2022 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product...